Arena Pharmaceuticals, Inc.
http://www.arenapharm.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Arena Pharmaceuticals, Inc.
US FDA Bids Adieu To Allergenic Products Adcomm; Vaccines Panel To Take Over Duties
The effort and expense to maintain the committee, which met only 10 days in the past 15 years, can no longer be justified, the FDA said. The terminated panel’s responsibilities will be integrated into the Vaccines and Related Biological Products Advisory Committee.
Sage’s Biogen-Partnered Essential Tremor Drug Fails In Phase II
For Sage, the mid-stage failure of SAGE-324 in essential tremor is its second setback in a year full of clinical trial readouts. For Biogen, it highlights a lack of later-stage pipeline prospects.
Decoding Regulatory Agency Decisions: The Case of Amylyx’s Relyvrio/Albrioza in the US and EU
Relyvrio/Albrioza, Amylyx’s ill-fated treatment for amyotrophic lateral sclerosis, was approved for marketing by the US Food and Drug Administration but rejected by the European Medicines Agency. The Pink Sheet explores how the two agencies applied the available regulatory flexibilities and the impact of other factors, such as regulatory precedence and patient influence, on decision-making.
Top FDA Staff Are Pushing Review Teams To Be Comfortable With Regulatory Flexibility
Senior leadership in the FDA’s drugs, biologics and devices centers want reviewers to feel more comfortable taking risks in product approvals, but may need more concrete examples of regulatory flexibility's success to convince them.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Beacon Discovery Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice